Background {#Sec1}
==========

Many reports suggest that the outcomes of treatment for ovarian cancer (OC) differ between patients who are carriers of *BRCA1/2* mutations and patients with sporadic OC (SOC). Most investigators report a better outcome for patients with *BRCA1/2*-dependent OC (*BRCA1/2*-OC). The *BRCA1* and *BRCA2* mutations are thought to cause an impaired ability to repair DNA damage, and as a result, *BRCA1/2*-OC is more sensitive than SOC to chemotherapeutic drugs that act directly on the DNA double helix, such as cisplatin and carboplatin \[[@CR1], [@CR2]\].

To date, most studies of the effect of *BRCA1* and *BRCA2* mutations on OC treatment outcomes have been carried out among American, British and Ashkenazi Jewish women. The significance of germline mutation of the *BRCA2* gene in the Polish population has not yet been established and, unlike mutation of the *BRCA1* gene, it is not routinely screened for among OC patients. Apart from one observational study in a small group of patients, there are no data on treatment outcomes for Central and Eastern European women with *BRCA1*-OC \[[@CR3]\]. It is possible that genetic diversity might lead to different treatment outcomes in this population compared with previously studied populations. Moreover, there are limited data available on prognostic factors among patients with *BRCA1*-OC and it has not yet been determined whether prognostic factors in patients with *BRCA1*-OC differ from those in patients with SOC. Therefore, the aim of this study was to analyse the prognostic factors for favourable treatment outcomes in Polish patients with *BRCA1*-OC.

Methods {#Sec2}
=======

The records of all patients with OC treated with surgery and chemotherapy at the Centre of Oncology in Kraków, Poland, from 2004 to 2009 were reviewed. In total, there were records for 1225 patients with OC diagnosed based on examination of the surgical specimen or biopsy. From the 1225 records, a group of 249 consecutive patients who fulfilled the criteria of high risk for hereditary OC based on family history were identified. After written, informed consent was obtained blood was collected from these 249 patients for *BRCA1* mutation analysis. Exons 2, 5, 11 and 20 of the *BRCA1* gene were analysed, and the most frequent *BRCA1* gene mutations among the Polish population were searched for: 4153delA, 5382insC C61G, 185delAG and 3819del5. The DNA analysis was carried out using denaturing high-performance liquid chromatography (dHPLC), restriction fragment length polymorphism (RFLP) and sequencing. The patients with *BRCA1* mutations were selected as the study group. The study was approved by the Ethics Committee of Maria Skłodowska-Curie Memorial Institute.

Response to combination therapy (surgery and chemotherapy) used to treat *BRCA1*-OC was assessed based on clinical examination, imaging (Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria 1.0) and marker analysis (serum CA125 concentration). Patients were evaluated every three months for 2 years and every 6 months thereafter. All patients in the study group were observed for at least 3 years or until death.

The effectiveness of treatment was evaluated according to time to progression, defined as the period between the beginning of treatment and clinical or imaging identification of recurrence of cancer, and 5-year overall survival from the beginning of treatment. The mean follow-up period was 65 months. Survival probability was estimated using the Kaplan--Meier method \[[@CR4]\]. Peto's log-rank test was used to assess the statistical significance of differences among the results \[[@CR5]\]. The level of statistical significance was set at *p* \< 0.05. The Cox proportional hazards model was used to assess the impact of selected factors on patient survival \[[@CR6]\].

Results and discussion {#Sec3}
======================

Among the 249 consecutive patients at high risk of hereditary OC who were screened for germline mutation of the *BRCA1* gene, 69 (27.7 %) had mutations. However, three women from this group did not complete the treatment and were excluded from the study (one refused chemotherapy and two died shortly after surgery without having completed adjuvant treatment). Therefore, the final study group included 66 patients with *BRCA1*-OC. Before beginning treatment, all patients had a histopathological diagnosis of OC. The median age was 49.5 years (mean 48 years, range 23--75 years). All study patients underwent planned combination therapy and were further observed. They received from three to nine courses of adjuvant therapy. Population, microscopic and clinical characteristics of the 66 patients with *BRCA1*-OC are presented in Table [1](#Tab1){ref-type="table"}.Table 1Population, microscopic and clinical characteristics of *BRCA1*-OC patientsNo. of patientsPercentPopulation, microscopic and clinical characteristics66100Age - ≤ 50 years3451.5 - \> 50 years3248.5Menopause - yes2842.4 - no3857.6No. of births - 01015.2 - 12740.9 - ≥22943.9Family history - 1st degree relatives with ovarian cancer812.1 - 1st degree relatives with breast cancer1725.8Coexisting breast cancer - yes913.6Type of *BRCA1* gene mutation -C61G3147 - 5382insC2131.8 - 4153delAG69.1 - 189delAG46.1 - 3819del523 - IVS20 + 60ins1211.5 - 4158A \> G11.5Grading of the tumor - G122.7 - G21827.3 - G34670Histological type - serous2740.9 - endometrial2334.9 - undifferentiated812.1 - mucous46.1 - clear cell23 - mezonefroid23Staging FIGO (2009) - I46.1 - II1116.7 - III5075.7 - IV11.5Cytoreduction - primary4466.7 - interval2233.3The overall extent of cytoreduction - optimal3451.5 - suboptimal3248.5The average concentration of CA125 at the beginning of treatment1113 U/mlThe average concentration of CA125 at the end of treatment71 U/ml

During follow-up, progression occurred in 48 (72.7 %) of the study group. The mean time to progression was 26.2 months (median 20 months). The 5-year survival rate was 43.9 % and the median survival time was 32.3 months. The overall survival Kaplan--Meier curve is presented in Fig. [1](#Fig1){ref-type="fig"}. Table [2](#Tab2){ref-type="table"} shows a comparison of the most significant publications on *BRCA1/2-*dependant OC in terms of survival.Fig. 1Overall survival of patients with BRCA1-OCTable 2Comparison of long-term outcome in patients with *BRCA-*OCAuthor, year of publicationNo. of patientsPopulationOverall 5-year survivalMedian survivalRubin 1996 \[[@CR23]\]53*BRCA1/2*-OC\~60 %^a^\~80 months^a^Pharoah 1999 \[[@CR7]\]127*BRCA1/2*-OC21 %20,6 monthsBoyd 2000 \[[@CR10]\]67*BRCA1*-OC\~50 %^a^\~60 months^a^Ramus 2001 \[[@CR24]\]15*BRCA1*-OC\~25 %^a^52 monthsCass 2003 \[[@CR11]\]33*BRCA1/2*-OC65 %91 monthsMajdak 2005^b^ \[[@CR3]\]18*BRCA1*-OC\~33 %^a^\~28 months^a^Chetrit 2008 \[[@CR8]\]213*BRCA1/2*-OC46 %53,7 monthsTan 2008 \[[@CR25]\]22*BRCA1/2*-OC\~65 %^a^8,4 yearsKringen 2005 \[[@CR26]\]30*BRCA1/2*-OC33,3 %-Lacour 2011 \[[@CR27]\]95*BRCA1/2*-OC\~25 %^a^101,7 monthsHyman 2012 \[[@CR9]\]30*BRCA1*-OC\~60 %^a^6 yearsVencken 2013 \[[@CR28]\]245*BRCA1*-OC62 %6 yearsBolton 2012 \[[@CR29]\]909*BRCA1*-OC44 %4,6 yearsOwn material66*BRCA1*-OC43,9 %32,3 months^a^ Data extrapolated from the Kaplan-Meier curves^b^ Polish patients population

The population, microscopic and clinical factors that were significant on univariate analysis are presented in Table [3](#Tab3){ref-type="table"}. Multivariate analysis showed a positive, statistically significant impact of the endometrial subtype of OC and serum CA125 (\<12.5 U/ml at the end of treatment) on 5-year overall survival from *BRCA1-*OC. Both of these factors were independent prognostic factors for 5-year overall survival (Table [4](#Tab4){ref-type="table"}).Table 3Results of treatment of patients with *BRCA1*-OC depending on the population, microscopic and clinical characteristicsPopulation, microscopic and clinical characteristicsNo. of patients5-year overall survivalNo. of patients%The number of patients with *BRCA1* gene mutation662943.9^a^ Coexisting neoplasms - no572849.1 - breast cancer9111.1^a^ The total extent of cytoreduction - optimal342058.8 - suboptimal32928.1^a^ Staging FIGO (2009) - I44100.0 - II8562.5 - III501938.0 - IV4125.0^a^ Histological type - serous271140.7 - endometrial231460.9 - undifferentiated8112.5 - mucous4250.0 - clear cell2150.0 - mezonefroid200^a^ CA125 concentration at the beginning of treatment - \< 285,5312167.7 - ≥285,535822.9^a^ CA125 concentration at the end of treatment - \<12,5342264.7 - ≥12,522731.8^a^ Statistically significant differences, log rank test, *p* \<0.05Table 4Results of the multivariate analysis of prognostic factors in the group of 66 patients with *BRCA1*-OCVariableVariantRelative risk (RR)Confidence interval*p* valueHistological typeUndifferentiated adenocarcinoma39,292,07--743,35*p* = 0.014Serous adenocarcinoma1Histological typeEndometrial adenocarcinoma0,20,04--0,85*p* = 0.03Serous adenocarcinoma1Level of CA125 at the end of treatment\<12,5 U/ml0,230,07--0,69*p* = 0.01

The composition of the study group did not differ from previously published studies in terms of population, histopathologic and clinical factors. The number of *BRCA1-*OC patients in the present study was relatively high compared to previous studies, most of which included 13--43 patients, with only a few recruiting higher numbers of 88--245 patients. Among these previous studies, a small number evaluated the clinical features and outcome of patients with *BRCA1*-OC separately from patients with *BRCA2*-OC. However, these studies were conducted among Jewish, American and Western European populations, which seem to be genetically different from the Polish population \[[@CR7]--[@CR9]\].

Consistent with previous reports, the serous subtype of OC was predominant among the study patients (*n* = 27, 40.9 %). The percentage of the serous subtype reported in the literature varies widely from 25 to 93 %, which might be related to the size of patient groups. However, in contrast to previous reports, the percentage of patients with the endometrial subtype of OC (34.9 %) was high in the present study, whereas previous studies have found that 14 % or less of patients with *BRCA1*-OC have this subtype \[[@CR10]\]. Interestingly, another Polish population analysis of patients with *BRCA1*-OC reported an unusually high percentage of mucinous cancers (17 %). However, that study was small with only 18 patients \[[@CR3]\]. Both findings are unusual because somatic tumour mutations of the *BRCA1* gene are rare in endometrial and mucinous subtypes of OC.

Prognostic factors in patients with *BRCA1*-OC {#Sec4}
----------------------------------------------

To date, few studies have investigated prognostic factors associated with *BRCA1/2*-OC. Most research has focussed on differences in treatment outcomes between OC patients with and without *BRCA1/2* mutations. Furthermore, few studies have looked at differences in prognostic factors between patients with SOC and *BRCA1/2*-OC.

The strongest prognostic factor for treatment outcomes in patients with SOC is the FIGO cancer stage. On univariate analysis in the present study, the FIGO cancer stage was a prognostic factor for 5-year overall survival of *BRCA1*-OC patients. However, this was not confirmed in the multivariate analysis, possibly as a result of the small number of patients with early-stage disease (4 patients had stage I disease and 8 had stage II disease).

Similar to SOC patients, in the present study optimal surgical cytoreduction (remnants after surgery ≤1 cm) had a positive prognostic impact on survival in patients with *BRCA1*-OC. The difference in the 5-year survival rate between patients with and without optimal surgical cytoreduction was 30 %, which is similar to that reported in the literature for SOC \[[@CR11], [@CR12]\]. Only one previous study investigated the impact of the extent of surgical cytoreduction on survival in patients with *BRCA1/2*-OC \[[@CR10]\]. That study identified a statistically significant higher risk of death among patients with surgery that was not considered complete, with a hazard ratio (HR) = 1.48 on multivariate analysis. However, in the present study, the prognostic value of cytoreduction was not confirmed on multivariate analysis, probably because of the limited number of cases.

Of the patients with *BRCA1*-OC in the present study, nine (13.6 %) patients had been previously treated for breast cancer, and had achieved a complete and long-lasting remission. In all nine patients, the breast cancer was treated with surgery and one line of anthracycline-based chemotherapy. None of the patients had received platinum agents. Imaging, clinical findings, serum markers and immunohistochemical analysis of ovarian tumours confirmed that all nine patients had primary OC rather than secondary breast cancer. The 5-year survival rate in this group was significantly lower compared with the other *BRCA1*-OC patients (11.1 % vs. 49.1 %, respectively). It should be noted that progression of OC can mask the recurrence of breast cancer resulting in poorer outcomes.

Among patients with *BRCA1*-OC, Chetrit et al. found that the serous subtype of OC was associated with a poorer prognosis compared to the non-serous subtype (5-year overall survival rate of 44.9 % vs. 50 %, respectively), and poorly differentiated tumours were associated with a poorer prognosis than well differentiated and moderately differentiated subtypes (5-year overall survival rate of 45.4 % vs. 55 %, respectively) \[[@CR8]\]. In terms of the importance of microscopic subtypes of OC on prognosis, the results of the present study agreed with previous studies on SOC. On univariate analysis the endometrial subtype of OC was associated with a better prognosis compared to the serous subtype of OC, and the poorest prognosis was associated with the undifferentiated adenocarcinoma subtype. The numbers of patients in the present study with mucous, clear-cell and mesonephroid types of *BRCA1*-OC were too small to draw statistical conclusions. Endometrial tumours are more likely to develop in the pelvis without spread to the upper abdomen and they are more likely to be diagnosed at an early stage. Similarly, on multivariate analysis, a statistically significant positive impact on the 5-year overall survival was associated with the endometrial subtype of the OC. The impact of histological grade (G) on treatment outcomes was not statistically significant on univariate or multivariate analysis.

The serum CA125, both at the beginning of treatment and after treatment completion, is a widely confirmed prognostic factor in patients with OC \[[@CR13]--[@CR20]\]. For patients with *BRCA1*-OC, the reported average serum CA125 before treatment ranges from 445 U/ml to 824 U/ml \[[@CR11], [@CR21], [@CR22]\]. However, there are no data on serum CA125 levels at the end of treatment. In the present study, the average serum CA125 in patients with *BRCA1*-OC was 113 U/ml and 71 U/ml before and after treatment, respectively. No previous studies have reported that serum CA125 levels were a prognostic factor in patients with *BRCA1/2*-OC. However, on univariate analysis in the present study a relatively low serum CA125 at the beginning of treatment and after treatment was associated with better prognosis (67.7 % vs. 22.9 % 5-year overall survival for serum CA125 ≤ 285.5 U/ml vs. \>285.5 U/ml at the beginning of treatment, and 64.7 % vs. 31.8 % 5-year overall survival for serum CA125 of ≤12.5 U/ml vs. \>12.5 U/ml after treatment).

Conclusions {#Sec5}
===========

Prognostic factors for treatment outcomes in Polish patients with *BRCA1*-OC do not appear to differ from those in patients with SOC. The incidence of the endometrial subtype of OC was relatively high, which is a new finding not previously reported in the literature. This form of OC was also an independent, positive prognostic factor on multivariate analysis.
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